[Extracranial stereotactic body radiotherapy in oligometastasis]

Piatigorsky Grinberg N, Ciapponi A, Colaci C, Alfie V, García Martí S, Bardach A, Augustovski F, Alcaraz A, Pichon-Riviere A
Record ID 32018002333
Original Title: Radioterapia estereotáxica extracraneal en oligometástasis
Authors' recomendations: Moderate-quality evidence shows that extracranial stereotactic body radiotherapy potentially results in a higher net benefit by increasing overall survival after five years in patients with oligometastasis regardless of the type of primary tumor without affecting quality of life. It might also decrease the rate of progression in patients with oligometastatic androgen-sensitive prostate cancer. The economic evaluations surveyed suggest that extracranial stereotactic body radiotherapy might be more cost-effective in patients with metastatic spread of primary lung adenocarcinoma than segmentectomy but it would not be cost-effective in other histologies or in lung metastasis resulting from colorectal cancer. The clinical practice guidelines assessed recommend the use of extracranial stereotactic body radiotherapy in patients with lung metastases resulting from colorectal cancer. Health funders from Europe and the United States cover this technology in lung and liver metastases. In some cases, coverage is also extended to kidney, adrenal gland and pancreas metastasis.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Neoplasms
  • Radiosurgery
  • Neoplasm Recurrence, Local
  • Neoplasm Metastasis
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.